Back to top
more

Verrica Pharmaceuticals (VRCA)

(Delayed Data from NSDQ)

$5.64 USD

5.64
13,658

+0.01 (0.18%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $5.60 -0.04 (-0.71%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of 28.57% and 22.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -133.33% and 5.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -2.38% and 98.70%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates

by Zacks Equity Research

Amneal (AMRX) delivered earnings and revenue surprises of 40% and 2.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Verrica Pharmaceuticals (VRCA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Equity Research

Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of 4% and 80.78%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aquestive Therapeutics (AQST) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -35.71% and 12.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -20.83% and 2.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Verrica Pharmaceuticals (VRCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of 27.91% and 10.15%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -2.13% and 8.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 3.85% and 1.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of 68.42% and 11.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ardelyx (ARDX) delivered earnings and revenue surprises of 30% and 31.38%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?

by Zacks Equity Research

Zevra Therapeutics (ZVRA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of 29.63% and 41.97%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Xeris Biopharma (XERS) delivered earnings and revenue surprises of -16.67% and 2.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -88.89% and 1.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?

by Zacks Equity Research

Verrica Pharmaceuticals (VRCA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength?

by Zacks Equity Research

Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Ligand (LGND) Up 9% on FDA Nod for Molluscum Infection Gel

by Zacks Equity Research

Following the FDA approval, Ligand's (LGND) Zelsuvmi is the first at-home treatment option available for molluscum contagiosum.

Zacks Equity Research

Best Momentum Stocks to Buy for April 18th

by Zacks Equity Research

VRCA, BZ and ANVS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 87, 2023.

Zacks Equity Research

Catalyst Pharmaceuticals (CPRX) Q2 Earnings Top, Revenues Up

by Zacks Equity Research

Catalyst (CPRX) beat earnings and sales estimate in second-quarter 2022 earnings. Consequently, the stock surges.

Zacks Equity Research

Corcept (CORT) Down on Q2 Earnings Miss, Revenues Rise Y/Y

by Zacks Equity Research

Corcept's (CORT) earnings miss estimates in second-quarter 2022 while revenues beat the same. Shares down.

Zacks Equity Research

Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up

by Zacks Equity Research

Zoetis' (ZTS) earnings miss estimates in second-quarter 2022. The revenues beat estimates owing to the strong uptake of the company's companion animal portfolio products.